Amarin Corp Plc (AMRN)

[ziploc_1]

When/if Vascepa begins to be marketed in mainland China, it will be at lower prices than are presently charged in Europe or in the U.S.

When/if that happens, Amarin will start marketing an authorized generic Vascepa in the U.S....Vascepa will be sold in much higher volumes, leading to lower prices paid by Amarin for API and for finished product...as opposed to the prices available to generics...It will be very difficult for those multiple generics to compete on price and still make money... This is even if they continue to offer lower prices for EXCLUSIVITY deals for all their own generic products to pharmacy benefit plans, as they do now, so that these PBMs will carry all their products... and FREEZE out competing generics FROM OTHER COMPANIES.

At that point Vascepa becomes a global blockbuster, albeit at lower prices.